Supreme Court Declines to Hear Lawsuits Against Medicare Drug Price Negotiation Program

The U.S. Supreme Court on Monday refused to hear challenges to the Medicare drug price negotiation program, delivering a setback to the pharmaceutical industry's legal effort.

The Court declined to review cases brought by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis and Novo Nordisk, all of which had sought to block the program.

With the high court's denial, the drugmakers' remaining lawsuits are likely to face greater difficulty, reinforcing the program's trajectory despite industry opposition.